论文部分内容阅读
Objectives The usefulness of daunorubicin in acute nonlymphocytic leukemia patients is limited by their cardiotoxicity.Current prophylaxis relies upon early detection of systolic and/or diastolic dysfunction.Dexrazoxane reduces cardiac damage during treatment with daunorubicin.